{"id":"perindopril-plus-hydrochlorothiazide","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Hyperuricemia"},{"rate":"5-15","effect":"Hypokalemia"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"3-8","effect":"Fatigue"},{"rate":"0.1-0.5","effect":"Angioedema"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Perindopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that increases urinary sodium and water excretion, decreasing intravascular volume and blood pressure. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:51.679Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure (perindopril component)"}]},"trialDetails":[{"nctId":"NCT03295734","phase":"PHASE2","title":"ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2018-05-29","conditions":"Hypertension, Aging, Sedentary Lifestyle","enrollment":223},{"nctId":"NCT02742467","phase":"PHASE4","title":"Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans","status":"COMPLETED","sponsor":"University of Abuja","startDate":"2017-06-07","conditions":"Hypertension","enrollment":702},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241},{"nctId":"NCT03921736","phase":"PHASE4","title":"Reversal of an Unfavorable Effect of Hydrochlorothiazide Compared to Angiotensin Converting Enzyme Inhibitor on Serum Uric Acid and Oxypurines Levels by Estrogen-progestin Therapy in Hypertensive Postmenopausal Women.","status":"COMPLETED","sponsor":"Anna Posadzy-Małaczyńska","startDate":"2000-01-10","conditions":"Hypertension, Hyperuricemia, Menopause","enrollment":180},{"nctId":"NCT02449811","phase":"","title":"RAS Peptide Profiles in Patients With Arterial Hypertension","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":"Essential Hypertension","enrollment":107},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT03249285","phase":"PHASE3","title":"Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2016-03","conditions":"Hypertension","enrollment":300},{"nctId":"NCT01891513","phase":"","title":"ACE Inhibitors Combined With Exercise for Seniors - Pilot Study","status":"COMPLETED","sponsor":"University of Florida","startDate":"2014-01","conditions":"Hypertension, Aging","enrollment":104},{"nctId":"NCT01819441","phase":"PHASE4","title":"Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients","status":"UNKNOWN","sponsor":"Yining Huang","startDate":"2012-05","conditions":"Cerebral Small Vessel Diseases","enrollment":1200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Perindopril plus Hydrochlorothiazide","genericName":"Perindopril plus Hydrochlorothiazide","companyName":"University of Abuja","companyId":"university-of-abuja","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perindopril inhibits angiotensin-converting enzyme (ACE) to reduce vasoconstriction and aldosterone secretion, while hydrochlorothiazide promotes sodium and water excretion to lower blood volume, together reducing blood pressure. Used for Hypertension, Heart failure (perindopril component).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}